Andrew Paul, CEO
Mr. Paul is an experienced entrepreneur who oversees the business practices of the company, including contracting, financial management, and internal business structures. Prior to starting, operating then selling his own company, Capitol Impact LLC., he worked for divisions of Dun & Bradstreet and VNU. He is experienced with profit-based business practices and finding talent.
Ishraq Alim, Ph.D., Senior Scientist
Dr. Alim joined the company in July 2019, following 10 years of experience in drug/therapy development and diagnostic development. During that time, he developed broad technical expertise in molecular biology, cell culture, flow cytometry, biochemical assays, in vitromodels, viral therapy and electrophysiology. At MMG, he has day-to-day responsibility for study design and execution to meet the goals of the company’s funded projects. He completed his Ph.D. at University of Toronto
Sarah Yam, Bioinformatician
Ms. Yam joined the company in September 2020. During her time at the company she has been integral to the activities of the current CR-B Phase II analytical and clinical validation study. Sarah has major roles in study design and data analysis.